Some of the best links we picked up around the internet
Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other...
As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.
Verve Therapeutics has announced the first human proof-of-concept data demonstrating durable reductions in cholesterol for its in vivo base-editing...
In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...
Webinar
Webinar | Wednesday September 6, 2023 | 2:00 pm–3:00 pm CEST / 8:00 am–9:00 am EDT